Effect of oral multi-herbal preparation on COVID-19

Phase 3

Recruiting

• Conditions: COVID-19.; Covid-19; U07.1

• Registration Number: IRCT20180712040449N2
• Lead Sponsor: Tehran University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 18 May 2020

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 68

Inclusion Criteria

Patients with one or more of the following symptoms in addition to acute respiratory disease (ARI):• RR> 30• PO2 <93%• Pulmonary infiltration in chest x-ray• Clinical judgment of a specialist
Age range of 18 to 75 years in both genders
Lack of any serious concomitant disease of the heart, brain, or lungs, metabolic disorders, and etc.
The patient’s ability and own will to fill out a personal consent form for inclusion in the study
Patient not intubated.

Exclusion Criteria

Pregnancy and lactation
Any history of allergy to any of the herbal product components
Inability to take a drug per-oral
Any condition that precludes continuance of medical intervention based on the judgment of a physician.
Need for intubation
Nausea and vomiting and oral intolerance
Resistant hypoxemia
Reduced level of consciousness
Hemodynamic instability
Hypercapnia - respiratory fatigue
Any manifestation of known side effects of any of the herbal product components

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
O2 saturation percentage. Timepoint: Clinical examination and pulse oximetry at baseline, days 3, 6, 9, 12 and 14. Method of measurement: Pulse Oximeter.;Lung inflammation. Timepoint: CT scan at baseline, days 7 and 14. Method of measurement: CT scan.